A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma

被引：1

作者：

Martin, Thomas ^{[1
]}

Richter, Joshua ^{[2
]}

Vij, Ravi ^{[3
]}

Cole, Craig ^{[4
]}

Atanackovic, Djordje ^{[5
]}

Zonder, Jeffrey ^{[6
]}

Kaufman, Jonathan L. ^{[7
]}

Bensinger, William ^{[8
]}

Dimopoulos, Meletios A. ^{[9
]}

San Miguel, Jesus ^{[10
]}

Zimmerman, Todd ^{[11
]}

Lendvai, Nikoletta ^{[12
]}

Hari, Parameswaran ^{[13
]}

Ocio, Enrique M. ^{[14
]}

Gasparetto, Cristina ^{[15
]}

Kumar, Shaji ^{[16
]}

Hsu, Karl ^{[17
]}

Charpentier, Eric ^{[17
]}

Strickland, Stephen A. ^{[18
]}

Mikhael, Joseph ^{[19
]}

机构：

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[3] Washington Univ, St Louis, MO USA

[4] Univ Michigan, Ctr Comprehens Canc, Internal Med Hematol & Oncolgy, Ann Arbor, MI 48109 USA

[5] Huntsman Canc Inst, Salt Lake City, UT USA

[6] Karmanos Canc Inst, Detroit, MI USA

[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[8] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[9] Univ Athens, Athens 11528, Greece

[10] Univ Navarra, E-31080 Pamplona, Spain

[11] Univ Chicago, Chicago, IL 60637 USA

[12] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[13] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[14] Univ Hosp Salamanca, Salamanca, Spain

[15] Duke Univ, Med Ctr, Durham, NC USA

[16] Mayo Clin, Div Hematol, Rochester, MN USA

[17] Sanofi Oncol, Cambridge, MA USA

[18] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[19] Mayo Clin, Scottsdale, AZ USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] SAR 650984, a Therapeutic Anti-CD38 Monoclonal Antibody, Blocks CD38-CD31 Interaction in Multiple Myeloma
An, Gang
Jiang, Hua
Acharya, Chirag
Zhong, Mike Y.
Cai, Ti
Yang, Guang
Song, Zhili
Theilhaber, Joachim
Adrian, Francisco
Tai, Yu-Tzu
Anderson, Kenneth C.
BLOOD, 2014, 124 (21)
[22] Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma
Shah, Bhavesh
Gray, Joy
Abraham, Ivo
Chang, Melody
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 170 - 182
[23] GEN3014 (HexaBody ®-CD38) in Anti-CD38 Mab-Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial
Grosicki, Sebastian
Plesner, Torben
Jurczak, Wojciech
Radocha, Jakub
Malek, Ehsan
Hiemstra, Ida
Brady, Lauren K.
Chen, Jenny
Gong, Nian
Hindsberger, Charlotte
Spencer, Andrew
BLOOD, 2023, 142
[24] A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma.
Richardson, Paul G.
Attal, Michel
Miguel, Jesus San
Campana, Frank
Le-Guennec, Solenn
Hui, Ai-Min
Risse, Marie-Laure
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[25] Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Dimopoulos, Meletios A.
Bringhen, Sara
Anttila, Pekka
Capra, Marcelo
Cavo, Michele
Cole, Craig E.
Gasparetto, Cristina J.
Hungria, Vania T. M.
Jenner, Matthew
Vorobyev, Vladimir
Ruiz, Eduardo Yanez
Yin, Jianyun
Hamlett, Anthony
Vij, Ravi
BLOOD, 2018, 132
[26] CLINICAL OUTCOMES ASSOCIATED WITH ANTI-CD38 RETREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REVIEW OF THE LITERATURE
McNamara, S.
Chorazy, J.
Pandey, A.
Bitetti, J.
Boytsov, N.
Purser, M.
Iheanacho, I.
VALUE IN HEALTH, 2024, 27 (06) : S31 - S31
[27] Determinants of Response to Anti-CD38 and Bispecific Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
Aleman, Adolfo
Zajdman, Ariel Kogan
Mouhieddine, Tarek
Upadhyaya, Bhaskar
Van Oekelen, Oliver
Lagana, Alessandro
Grossman, Leah
Thibaud, Santiago
Sanchez, Larysa
Richard, Shambavi
Rossi, Adriana
Richter, Joshua
Cho, Hearn Jay
Rodriguez-Valdes, Cesar
Chari, Ajai
Parekh, Samir
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S41 - S41
[28] COST OF ANTI-CD38 MONOCLONAL ANTIBODIES IN COMBINATION WITH CARFILZOMIB AND DEXAMETHASONE FOR RELAPSED REFRACTORY MULTIPLE MYELOMA
Lin, P.
Petitjean, A.
Drea, E.
Lin, F.
VALUE IN HEALTH, 2024, 27 (06) : S148 - S148
[29] A phase II dose-ranging trial of single-agent pamidronate for relapsed/refractory multiple myeloma.
Berenson, J
Webb, I
Henick, K
Vescio, R
Swift, R
Anderson, K
Seaman, J
BLOOD, 1998, 92 (10) : 107A - 107A
[30] SAR650984, a humanized anti-CD38 antibody, shows potent in vitro activity by multiple mechanisms against various hematologic tumor cell lines.
Deckert, Jutta
Yi, Yong
Chicklas, Sharon
Mayo, Michele
Chittenden, Thomas
Park, Peter
CANCER RESEARCH, 2009, 69

← 1 2 3 4 5 →